3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
15
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Endometrial Hyperplasia
2
Breast Neoplasms
2
Venous Thrombosis
1
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
33
Paclitaxel
27
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Fulvestrant
15
fludarabine
14
Trastuzumab
14
aldesleukin
13
Docetaxel
13
Early Intervention, Educational
12
Surveys and Questionnaires
11
veliparib
10
palbociclib
10
Methods
10
Gemcitabine
10
Blood Specimen Collection
10
Nivolumab
9
Flow Cytometry
9
Biopsy
9
Bevacizumab
9
sargramostim
8
niraparib
7
liposomal doxorubicin
7
Therapeutics
7
Taxes
7
Standard of Care
7
Psychiatric Rehabilitation
7
Magnetic Resonance Spectroscopy
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Atorvastatin
×
Gynecologic
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn